Pharvaris N.V., a Netherlands-based late-stage biopharmaceutical company, specializes in rare diseases such as hereditary angioedema. It reported substantial net losses deepening to €175.7 million in 2025 driven by increased R&D investment, particularly clinical development expenses. The company’s cash reserves rose modestly to €291.7 million by year-end 2025 following equity financing activities that underpin its near-term liquidity. With no product revenues yet, Pharvaris’ growth prospects hinge on upcoming regulatory milestones and commercial launches for its proprietary treatments like deucrictibant. Operational execution risks and potential funding needs remain key challenges.